Treatment of Lung Cancer Using Anti-PD-1 Antibody Combination
Summary
The USPTO published Bristol-Myers Squibb Company's patent application (US20260092114A1) for a method of treating lung cancer using a combination of an anti-PD-1 antibody administered by infusion in under 60 minutes and optionally an anti-CTLA-4 antibody administered in under 90 minutes. The application was filed on September 29, 2025.
What changed
Bristol-Myers Squibb Company filed a patent application for a lung cancer treatment method combining an anti-PD-1 antibody with optional anti-CTLA-4 antibody administration, both delivered via relatively short infusions. The invention specifies therapeutic amounts and administration parameters targeting PD-1 receptor inhibition. The assignee and sole inventor are listed as Bristol-Myers Squibb Company and Faith E. Nathan, respectively.
This is a patent publication rather than a regulatory action, so no compliance actions are required from industry participants. Pharmaceutical companies developing similar immunotherapy combinations should review the claims to assess potential patent landscape implications for their own development programs. No filing deadlines or regulatory obligations are associated with this document.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTI-CANCER AGENT
Application US20260092114A1 Kind: A1 Apr 02, 2026
Assignee
Bristol-Myers Squibb Company
Inventors
Faith E. NATHAN
Abstract
This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity which can be administered by infusion for less than 60 minutes; and, optionally, (b) another anti-cancer agent which is administered by infusion for less than 90 minutes. The other anti-cancer agent can be an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody.
CPC Classifications
C07K 16/2818 A61P 35/00 A61K 2039/507 A61K 2039/545 C07K 2317/33
Filing Date
2025-09-29
Application No.
19343049
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.